Ernexa Therapeutics Inc. (ERNA) › Cost of RevenueErnexa Therapeutics Inc. (ERNA): Cost of RevenueAnnual figures by period end, from SEC filings.$96.0KYear ended 2024-12-31$236.0K2022-12-31: $02023-12-31: $236.0K2024-12-31: $96.0K$96.0K2022-12-31 Cost of Revenue (USD) 2024-12-31Period endedCost of RevenueChange YoYSource filing2024-12-31$96.0K-59.3%2026-03-13, From 2024-01-012023-12-31$236.0Kn/a2025-03-12, From 2023-01-012022-12-31$0n/a2024-03-14, From 2022-01-01Other metrics: RevenueGross ProfitR&D ExpenseOperating IncomeDepreciation & AmortizationEBITDANet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesLong-Term DebtShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresFree Cash FlowShares OutstandingWeighted Average Diluted SharesEPS (Basic)